HINTZE and VATNER flex coronary artery with 5-0 suturing ( Ethicon
T. Hintze,S. Vatner
Abstract:The effects of 0.25 mg/kg dipyridamole on left ventricular (LV) pressures, LV dP/dt, heart rate, aortic pressures, left circumflex coronary blood flow, and left circumflex coronary arterial diameters and on calculations of late diastolic coronary resistance and large coronary cross-sectional area were studied in 15 conscious dogs. Injection of dipyridamole, a drug that has a mechanism of action dependent on myocardial adenosine production, caused sustained increases in mean coronary blood flow (244 + 28%), large coronary arterial cross-sectional area (28 ± 3.2%), heart rate (32 + 3.6%), and LV dP/dt (23 + 3.0%) and reductions in late diastolic coronary resistance (73 + 2.4%) and mean arterial pressure (14 ± 1.9%). Neither ,3-adrenergic-receptor blockade alone nor in conjunction with constant heart rate affected the dilation of large coronary arteries to dipyridamole significantly. Ganglionic blockade with hexamethonium also had little effect on the response of large and small coronary vessels to dipyridamole. Surprisingly neither ,8-adrenergic-receptor nor ganglionic blockade abolished the rise in LV dP/dt observed after dipyridamole. Aminophylline, however, effectively eliminated the dilation of large coronary arteries and resistance coronary vessels in response to dipyridamole. In summary, as long as dipyridamole does not induce severe sustained hypotension it exerts potent effects on both coronary arterial resistance and large coronary arteries in the conscious dog. The coronary dilation is independent of reflex adrenergic activation, but appears dependent on myocardial adenosine production. Circulation 68, No. 6, 1321-1327, 1983. DIPYRIDAMOLE, a drug that has a mechanism of action involving the metabolism of adenosine,l induces sustained, near-maximal vasodilation of coronary resistance vessels.2 However, studies in anesthetized animals5-9 and in man'0 suggest that dipyridamole elicits trivial or no dilation of large coronary arteries. These studies are consistent with the hypothesis that dipyridamole acts primarily on coronary resistance vessels, 9 i.e., the same locus as the proposed site of action of adenosine. "'3 Moreover, the deleterious effects of dipyridamole in the presence of myocardial ischemia have been attributed at least partially to its prominent action on coronary resistance vessels and its From the Departments of Medicine, Harvard Medical School, and Brigham and Women's Hospital, Boston, and the New England Regional Primate Research Center, Southboro, MA. Supported in part by U.S. Public Health Service grants HL 15416 and HL 17459. Address for correspondence: Stephen F. Vatner, M.D., New England Regional Primate Research Center, One Pine Hill Dr., Southboro, MA 01772. Received May 20, 1983; revision accepted Aug. 25, 1983. Dr. Hintze was supported by NIH postdoctoral fellowship HL 05936. Vol. 68, No. 6, December 1983 limited action on large coronary arteries.6, I Previous studies have examined the effects of dipyridamole in anesthetized animal preparations5-9 or in normal coronary segments from patients with coronary artery disease.10 The goal of our investigation was to examine the effects and mechanism of action of dipyridamole on instantaneous and continuous measurements of large coronary arterial diameters in intact, normal, conscious animals.